Effects of recombinant human tumor necrosis factor receptor type II antibody fusion protein on serum troponin I and tumor necrosis factor alpha expression in myocardial tissue in a rat model of myocardial ischemia/reperfusion injury

Yan Chen,Hao Xia,Bao Cui-yu,Chen Hong-guang,Wang Xin-liang,Xie Hua-qiang,Lan Liu
DOI: https://doi.org/10.3969/j.issn.1673-8225.2011.37.010
2011-01-01
Abstract:Background: A lot of tumor necrosis factor α (TNF-α) generating during myocardial ischemia/reperfusion can cause worsened myocardial systolic function. Objective: To investigate the effects of recombinant human tumor necrosis factor receptor type II antibody fusion protein on myocardial tissue in a rat model of myocardial ischemia/reperfusion injury. Methods: Myocardial ischemia/reperfusion injury was induced in adult male Wistar rats. In the drug intervention group, recombinant human tumor necrosis factor receptor type II antibody fusion protein was injected before reperfusion. In the model group, normal saline was given before reperfusion. A sham-operated group with myocardial ischemia/reperfusion injury induction was set. Immediately after reperfusion, myocardial infarction area was measured, TNF-α and serum cardiac troponin I were detected by ELISA, and TNF-α mRNA expression was determined by real time-PCR. Results and Conclusion: Compared with sham-operated group, TNF-α, TNF-α mRNA, and serum troponin I evels were significantly increased in the model and drug intervention groups (P < 0.05). Compared with model group, TNF-α and serum troponin I levels, myocardial infarction area and TNF-αmRNA expression were significantly decreased (P < 0.05), in the drug intervention group. Results showed that recombinant human tumor necrosis factor receptor type II antibody fusion protein can alleviate myocardial ischemia/reperfusion injury and improve cardiac function in rats.
What problem does this paper attempt to address?